IL2RA and neoplasm: Although anti-CD25 monotherapy demonstrated little effect on tumors at the beginning of treatment, the tumor volume growth accelerated late in the treatment course, therefore demonstrating that targeting CD25 was not sufficient to control or cure the tumor.